J&J Settles Risperdal Lawsuit for $7.8 Million

US pharmaceutical giant Johnson & Johnson has agreed to pay $7.8 million to settle a lawsuit over the marketing of its antipsychotic drug Risperdal to doctors in the US state of Arkansas.

The company said the settlement did not constitute an admission of wrongdoing.

According to the newspaper Arkansas Democrat-Gazette, which reported on the court filing, $2 million will go to a Texas law firm that represented Arkansas in the lawsuit filed more than seven years ago.

In 2012, a, jury in Arkansas' Pulaski County ruled that the company, through its Janssen Pharmaceutical subsidiary, committed medicaid fraud and violated a state law in its labeling and marketing of Risperdal.

The jury's $1.2 billion fine imposed on Johnson & Johnson was later overturned by the Arkansas Supreme Court.

Risperdal was first approved by the US Food and Drug Administration (FDA) to treat schizophrenia in 1993, and its registration later extended. The drug has been prescribed off label to treat attention deficit disorder in children, and has been linked by some to serious side effects such as enlarged breasts in boys as well as movement disorders such as tardive dyskinesia.

The FDA has now approved a longer-acting version of another of J&J's Janssen Pharmaceuticals unit's schizophrenia treatment Invega Trinza.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.